Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category

 

The Vibrant Philly Biotech Scene: Recent Happenings & Deals

Curator: Stephen J. Williams, Ph.D.

 

As the office and retail commercial real estate market has been drying up since the COVID pandemic, commercial real estate developers in the Philadelphia area have been turning to the health science industry to suit their lab space needs.  This includes refurbishing old office space as well as new construction.

Gattuso secures $290M construction loan for life sciences building on Drexel campus

Source: https://www.bizjournals.com/philadelphia/news/2022/12/19/construction-loan-gattuso-drexel-life-sciences.html?utm_source=st&utm_medium=en&utm_campaign=BN&utm_content=pl&ana=e_pl_BN&j=30034971&senddate=2022-12-20

 

By Ryan Mulligan  –  Reporter, Philadelphia Business Journal

Dec 19, 2022

Gattuso Development Partners and Vigilant Holdings of New York have secured a $290 million construction loan for a major life sciences building set to be developed on Drexel University’s campus.

The funding comes from Houston-based Corebridge Financial, with an additional equity commitment from Boston-based Baupost Group, which is also a partner on the project. JLL’s Capital Markets group arranged the loan.

Plans for the University City project at 3201 Cuthbert St. carry a price tag of $400 million. The 11-story building will total some 520,000 square feet, making it the largest life sciences research and lab space in the city when it comes online.

The building at 3201 Cuthbert will rise on what had served as a recreation field used by Drexel and is located next to the Armory. Gattuso Development, which will lease the parcel from Drexel, expects to to complete the project by fall 2024. Robert A.M. Stern Architects designed the building.

 

A rendering of a $400 million lab and research facility Drexel University and Gattuso Development Partners plan to build at 3201 Cuthbert St. in Philadelphia.

Enlarge

A rendering of a $400 million lab and research facility Drexel University and Gattuso Development Partners plan to build at 3201 Cuthbert St. in Philadelphia.

The building is 45% leased by Drexel and SmartLabs, an operator of life sciences labs. Drexel plans to occupy about 60,000 square feet, while SmartLabs will lease two floors totaling 117,000 square feet.

“We believe the project validates Philadelphia’s emergence as a global hub for life sciences research, and we are excited to begin construction,” said John Gattuso, the co-founder and president of Philadelphia-based Gattuso Development.

Ryan Ade, Brett Segal and Christopher Peck of JLL arranged the financing.

The project is another play in what amounts to an arms race for life sciences space and tenants in University City. Spark Therapeutics plans to build a $575 million, 500,000-square-foot gene therapy manufacturing plant on Drexel’s campus. One uCity Square, a $280 million, 400,000-square-foot life sciences building, was recently completed at 38th and Market streets. At 3151 Market St., a $307 million, 417,000-square-foot life sciences building is proposed as part of the Schuylkill Yards development.

Tmunity CEO Usman Azam departing to lead ‘stealth’ NYC biotech firm

 

By John George  –  Senior Reporter, Philadelphia Business Journal

Feb 7, 2022

The CEO of one of Philadelphia’s oldest cell therapy companies is departing to take a new job in the New York City area.

Usman “Oz” Azam, who has been CEO of Tmunity Therapeutics since 2016, will lead an unnamed biotechnology company currently operating in stealth mode.

In a posting on his LinkedIn page, Azam said, “After a decade immersed in cell therapies and immuno-oncology, I am now turning my attention to a new opportunity, and will be going back to where I started my life sciences career in neurosciences.”

Tmunity, a University of Pennsylvania spinout, is looking to apply CAR T-cell therapy, which has proved to be successful in treating liquid cancers, for the treatment of solid tumors.

Last summer, Tmunity suspended clinical testing of its lead cell therapy candidate targeting prostate cancer after two patients in the study died. Azam, in an interview with the Business Journal in June, said the company, which had grown to about 50 employees since its launch in 2015, laid off an undisclosed number of employees as a result of the setback.

Azam said on LinkedIn he is still a big believer in CAR T-cell therapy, noting Tmunity co-founder Dr. Carl June and his colleagues at Penn just published in Nature the 10-year landmark clinical outcomes study with the first CD19 CAR-T patients and programs.

“It’s just the beginning,” he stated. “I’m excited about the prospect of so many new cell- and gene-based therapies emerging in the next five to 10 years to tackle many solid and liquid tumors, and I hope we all continue to see the remarkable impact this makes on patients and families around the world.”

Azam could not be reached for comment Monday. Tmunity has engaged a search firm to identify his successor.

Tmunity, which is based in Philadelphia, has its own manufacturing operations in East Norriton. Tmunity’s founders include June and fellow Penn cell therapy pioneer Bruce Levine, who led the development of a CAR T-cell therapy now marketed by Novartis as Kymriah, a treatment for certain types of blood cancers.

In therapy using CAR-T cells, a patient’s T cells — part of their immune system — are removed and genetically modified in the laboratory. After they are re-injected into a patient, the T cells are better able to attack and destroy tumors. CAR is an acronym for chimeric antigen receptor. Chimeric antigen receptors are receptor proteins that have been engineered to give T cells their improved ability to target tumors.

Source: https://www.bizjournals.com/philadelphia/news/2022/02/07/tmunity-therapeutics-philadelphia-cell-azam-oz.html?utm_source=st&utm_medium=en&utm_campaign=BN&utm_content=pl&ana=e_pl_BN&j=30034971&senddate=2022-12-20

 

PIDC names U.S. Department of Treasury veteran, Philadelphia native as next president

 
By   –  Reporter, Philadelphia Business Journal

 

The Philadelphia Industrial Development Corp. has tapped U.S. Department of Treasury veteran Jodie Harris to be its next president.

Harris succeeds Anne Bovaird Nevins, who spent 15 years in the organization and took over as president in January 2020 before stepping down at the end of last year. Executive Vice President Sam Rhoads has been interim president.

Harris, a Philadelphia native who currently serves as director of the Community Development Financial Institutions Fund for the Department of Treasury, was picked after a regional and national search and will begin her tenure as president on June 1. She becomes the 12th head of PIDC and the first African-American woman to lead the organization.

PIDC is a public-private economic development corporation founded by the city and the Chamber of Commerce for Greater Philadelphia in 1958. It mainly uses industrial and commercial real estate projects to attract jobs, foster business opportunities and spur overall community growth. The organization has spurred over $18.5 billion in financing across its 65 years.

PIDC has its hand in development projects spanning the city, including master planning roles in expansive campuses like the Philadelphia Navy Yard and the Lower Schuylkill Biotech Campus in Southwest Philadelphia.

In a statement, Harris said that it is “a critical time for Philadelphia’s economy.”

“I’m especially excited for the opportunity to lead such an important and impactful organization in my hometown of Philadelphia,” Harris said. “As head of the CDFI Fund, I know first-hand what it takes to drive meaningful, sustainable, and equitable economic growth, especially in historically underserved communities.”

Harris is a graduate of the University of Maryland and received an MBA and master of public administration from New York University. In the Treasury Department, Harris’ most recent work aligns with PIDC’s economic development mission. At the Community Development Financial Institutions Fund, she oversaw a $331 million budget, mainly comprised of grant and administrative funding for various economic programs. Under Harris’ watch, the fund distributed over $3 billion in pandemic recovery funding, its highest level of appropriated grants ever.

Harris has been a part of the Treasury Department for 15 years, including as director of community and economic development policy.

In addition to government work, Harris has previously spent time in the private, academia and nonprofit sectors. In the beginning of her career, Harris worked at Meridian Bank and Accenture before turning to become a social and education policy researcher at New York University. She also spent two years as president of the Urban Business Assistance Corporation in New York.

Mayor Jim Kenney said that Philadelphia is “poised for long-term growth” and Harris will help drive it.

Source: https://www.bizjournals.com/philadelphia/news/2023/02/23/pidc-names-next-president-treasury.html 

$250M life sciences conversion planned for Philadelphia’s historic Quartermaster site

 
By   –  Reporter, Philadelphia Business Journal

Listen to this article     3 min

Real estate company SkyREM plans to spend $250 million converting the historic Quartermaster site in South Philadelphia to a life sciences campus with restaurants and a hotel.

The redevelopment would feature wet and dry lab space for research, development and bio-manufacturing.

The renamed Quartermaster Science + Technology Park is near the southwest corner of Oregon Avenue and South 20th Street in the city’s Girard Estates neighborhood. It’s east of the Quartermaster Plaza retail center, which sold last year for $100 million.

The 24-acre campus is planned to have six acres of green space, an Aldi grocery store opening by March and already is the headquarters for Indego, the bicycle share program in Philadelphia.

Six buildings totaling 1 million square feet of space would be used for research and development labs. There’s 500,000 square feet of vacant space available for life sciences and high technology companies with availabilities as small as 1,000 square feet up to 250,000 square feet contiguous. There’s also 150,000 square feet of retail space available.

The office park has 200,000 square feet already occupied by tenants. The Philadelphia Job Corps Center and Delaware Valley Intelligence Center are tenants at the site.

The campus was previously used by the military as a place to produce clothing, footwear and personal equipment during World War I and II. The clothing factory closed in 1994. The Philadelphia Quartermaster Depot was listed on the National Register of Historic Places in 2010.

“We had a vision to preserve the legacy of this built-to-last historic Philadelphia landmark and transform it to create a vibrant space where the best and brightest want to innovate, collaborate, and work,” SkyREM CEO and Founder Alex Dembitzer said in a statement.

SkyREM, a real estate investor and developer, has corporate offices in New York and Philadelphia. The company acquired the site in 2001.

Vered Nohi, SkyREM’s regional executive director of new business development, called the redevelopment “transformational” for Philadelphia.

 
 

Quartermaster would join a wave of new life sciences projects being developed in the surrounding area and across the region.

The site is near both interstates 76 and 95 and is about 2 miles north of the Philadelphia Navy Yard, which has undergone a similar transformation from a military hub to a major life sciences and mixed-use redevelopment project. The Philadelphia Industrial Development Corp. is also in the process of selecting a developer to create a massive cell and gene therapy manufacturing complex across two sites totaling about 40 acres on Southwest Philadelphia’s Lower Schuylkill riverfront.

At 34th Street and Grays Ferry Avenue, the University of Pennsylvania is teaming with Longfellow Real Estate Partners on proposed a $365 million, 455,000-square-foot life sciences and biomanufacturing building at Pennovation Works.

 

SkyREM is working with Maryland real estate firm Scheer Partners to lease the science and technology space. Philadelphia’s MPN Realty will handle leasing of the retail space. Architecture firm Fifteen is working on the project’s design.

Scheer Partners Senior Vice President Tim Conrey said the Quartermaster conversion will help companies solve for “speed to market” as demand for life science space in the region has been strong.

Brandywine pauses new spec office development, continues to bet big on life sciences

By   –  Reporter, Philadelphia Business Journal

 

Brandywine Realty Trust originally planned to redevelop a Radnor medical office into lab and office space, split 50-50 between the two uses.

After changes in demand for lab and office space, Brandywine (NYSE: BDN) recently completed the 168,000-square-foot, four-story building at 250 King of Prussia Road in Radnor fully for life sciences.

“The pipeline is now 100% life sciences, which, while requiring more capital, is also generating longer term leases at a higher return on cost,” Brandywine CEO Jerry Sweeney of the project said during the company’s fourth-quarter earnings call on Thursday.

At the same time, Brandywine is holding off on developing new office buildings unless it has a tenant lined up in advance.

The shift reflects how Philadelphia-based Brandywine continues to lean into — and bet big — on life sciences.

Brandywine is the city’s largest owner of trophy office buildings and has several major development projects in the works. The company is planning to eventually develop 3 million square feet of life sciences space. For now, 800,000 square feet of life sciences space is under development, including a 12-story, 417,000-square-foot life sciences building at 3151 Market St. and a 29-story building with 200,000 square feet of life sciences space at 3025 John F. Kennedy Blvd. Both are part of the multi-phase Schuylkill Yards project underway near 30th Street Station in University City.

Once its existing projects are completed, Brandywine would have 800,000 square feet of life sciences space, making up 8% of its portfolio.Sweeney said the company wants to grow that figure to 21%.

Brandywine is developing a 145,000-square-foot, build-to-suit office building at 155 King of Prussia Road in Radnor for Arkema, a France-based global supplier of specialty materials. The building will be Arkema’s North American headquarters. Construction began in January and is scheduled to be completed in late 2024.

Brandywine reported that since November it raised over $705 million through fourth-quarter asset sales, an unsecured bond transaction and a secured loan. The company has “complete availability” on its $600 million unsecured line of credit, Sweeney said.

Brandywine sold a 95% leased, 86,000-square-foot office building at 200 Barr Harbor Drive in West Conshohocken for $30.5 million. The company also sold its 50% ownership interest in the 1919 Market joint venture for $83.2 million to an undisclosed buyer. 1919 Market St. is a 29-story building with apartments, office and commercial space. Brandywine co-developed the property with LCOR and the California State Teacher’s Retirement System.

Brandywine declined to comment and LCOR could not be reached.

Brandywine’s core portfolio is 91% leased.

The project at 250 King of Prussia Road cost $103.7 million and was recently completed. The renovation included 12-foot high floor-to-ceiling glass on the second floor, a new roof, lobby, elevator core, common area with a skylight and an added structured parking deck.

Located in the Radnor Life Science Center, a new campus with nearly 1 million square feet of lab, research and office space, Sweeney said it’s a “magnet” for biotech companies. Avantor, a global manufacturer and distributor of life sciences products, is headquartered in the complex.

 

Sweeney said Brandywine is “very confident” demand will stay strong for life sciences in Radnor. The building at 250 King of Prussia Road is projected to be fully leased by early 2024.

“Larger users we’re talking to, they just tend to take a little bit more time than we would like as they go through technical requirements and space planning requirements,” Sweeney said.

While Brandywine is aiming to increase its life sciences footprint, the company is being selective about what it builds next. The company may steer away from developments other than life sciences. The Schuylkill Yards project, for example, features a significant life sciences portion in University City.

“Other than fully leased build-to-suit opportunities, our future development starts are on hold,” Sweeney said, “pending more leasing on the existing joint venture pipeline and more clarity on the cost of debt capital and cap rates.”

 

Brandywine said about 70% to 75%of suburban tenants have returned to offices while that number has been around 50% in Philadelphia. At this point, though, it hasn’t yet affected demand when leasing space. Some tenants, for example, have moved out of the city while others have moved in.

In the fourth quarter, Brandywine had $55.7 million funds from operations, or 32 cents per share. That’s down from $60.4 million, or 35 cents per share, in the fourth quarter of 2021. Brandywine generated $129 million in revenue in the fourth quarter, up slightly from $125.5 in the year-ago period.

Brandywine stock is up 6.4% since the start of the year to $6.70 per share on Monday afternoon.

Many of Brandywine’s properties are in desirable locations, which have seen demand remain strong despite challenges facing offices, on par with industry trends.

Brandywine’s 12-story, 417,000-square-foot building at 3151 Market St. is on budget for $308 million and on schedule to be completed in the second quarter of 2024. Sweeney said Brandywine anticipates entering a construction loan in the second half of 2023, which would help complete the project. The building, being developed along with a global institutional investor,would be used for life sciences, innovation and office space as part of the larger Schuylkill Yards development in University City.

The company’s 29-story building at 3025 John F. Kennedy Blvd. with 200,000 square feet of life sciences space and 326 luxury apartments, is also on budget, costing $287.3 million, and on time, eyeing completion in the third quarter of this year.

Source: https://www.bizjournals.com/philadelphia/news/2023/02/06/brandywine-realty-life-sciences-development.html

Read Full Post »

Unicorns Behavior in the MarketPlace: Research by Prof. Ilya Strebulaev at Stanford University, GSB

Reported by Aviva Lev-Ari, PhD, RN

 

The following observations are covered in a series of post by Prof. Strebulaev on LinkedIn:

  1. How Long Does It Take for Unicorns to Exit?

Ilya Strebulaev posted this • 23h23h

 

How Long Does It Take for Unicorns to Exit?

For a sample of 396 exited US unicorns, it takes an average (median) of about 9 (8) years since founding to exit, where exit means going public, acquisition, or liquidation/bankruptcy.

There is a lot of variation, though. For example, some unicorns exited faster.  YouTube  was acquired by  Google  less than 2 years after founding, and  Allogene Therapeutics  went public in less than 2 years.  Some companies had to wait a long time.  AvidXchange, Inc.  went public in about 21 years, and  LinkedIn  acquired  Lynda.com  approximately 20 years after  Lynda.com ’s founding.

NB: Many unicorns in the sample have not yet exited, so both mean and median will eventually increase.

This research has been done with the help of the  Stanford University Graduate School of Business  Venture Capital Initiative.

hashtag#unicorns   hashtag#venturecapital   hashtag#starups   hashtag#ipo   hashtag#acquisition…show more

    • 315
    • 8 comments

2. How Many Countries Have Produced Unicorn Founders?

Ilya Strebulaev posted this • 5d5d

 

How Many Countries Have Produced Unicorn Founders?

A couple weeks ago, I posted results of my research on the countries of birth of over a thousand founders of 500 US-based unicorns on LinkedIn. Almost half of unicorn founders, for whom my team and I were able to identify country of birth, were born outside the US. This generated a lot of interest and the list of top countries (India, Israel, Canada, UK, China, etc.) was shared widely.

As a follow up, have a look at all the countries that my team and I identified.

65 countries from all over the world have “produced” at least one founder of a US unicorn.

Takeaway: Immigrants from many countries contribute to the innovation ecosystem in the US.

European countries include Belgium (9 founders), Spain (9), Netherlands (7), Romania (5), Denmark (5), Italy (5), and Poland (5).

Asian countries include Iran (9), Lebanon (4), Japan (3), Pakistan (3), and Turkey (2).

African countries include South Africa (5) and Zimbabwe (2).

Latin America includes Brazil (9), Argentina (4), and Guatemala (2).

Australasia is represented by Australia (8) and New Zealand (6).

Important note: This list includes only founders of US-based unicorns.

This research has been done with the help of the  Stanford University Graduate School of Business  Venture Capital Initiative.

hashtag#unicorns   hashtag#venturecapital   hashtag#entrepreneurship   hashtag#founders…show more

    • 2,962
    • 151 comments

. 3.    What are Unicorn Valuations at Their Exit Times?

Ilya Strebulaev posted this • 1w1w

 

What are Unicorn Valuations at Their Exit Times?

For a sample of 531 US unicorns, 396 had exited (went public, were acquired, or closed) as of January 2022. At exit time, an average (median) unicorn was valued at $4 billion ($1.6 billion). Half had a valuation of less than $2 billion.

50 unicorns, or 13%, had a valuation below $1 billion. For example,  Casper  and  Reata Pharmaceuticals, Inc.  had a net IPO valuation of $375 million and $176 million, respectively, while  LivingSocial  was acquired for virtually nothing.

31 unicorns, or 8%, were in the “decacorn” range at time of exit, or over $10 billion.  Uber  was valued at about $68 billion,  Meta  at $65 billion, and  Coinbase  at $48 billion.

Takeaway: There is huge variation in unicorn valuations at exit time.

This research has been done with the support of  Stanford University Graduate School of Business  Venture Capital Initiative. NB: For public companies, I used net IPO valuation; for acquired/closed companies, I used gross valuation.

hashtag#unicorns   hashtag#startups   hashtag#venturecapital   hashtag#valuation   hashtag#ipo   hashtag#acquisition…show more

    • 420
    • 21 comments

4. Who is Acquiring Unicorns?

Ilya Strebulaev posted this • 1w1w

 

Who is Acquiring Unicorns?

For a sample of 396 exited US unicorns, 135 companies (34%) were acquired.

The majority of these acquirers are public companies, responsible for 105 (78%) of all unicorn acquisitions. 18 (23%) of these public companies acquired two or more unicorns.  Cisco  bought five unicorns, including  Duo Security , Cerent, and  AppDynamics .  Alphabet Inc.  purchased four unicorns:  YouTube ,  Nest Labs ,  Actifio , and  Looker .  Meta  acquired  Oculus VR ,  Instagram ,  WhatsApp , and  CTRL-labs .

Of these public acquirers, 56 (75%) are based in the U.S. There are five acquirers from the U.K., three from Canada, and three from Switzerland.

Two private equity funds,  Thoma Bravo  and  Vista Equity Partners , acquired two unicorns each.

Takeaway: Many large companies are actively acquiring unicorns (among other VC-backed companies, of course).

This research has been done with the help of the  Stanford University Graduate School of Business  Venture Capital Initiative.

hashtag#unicorns   hashtag#startups   hashtag#venturecapital   hashtag#acquisitions…show more

    • 731
    • 46 comments

SOURCE

https://www.linkedin.com/in/ilyavcandpe/

Read Full Post »

Greylock Partners Announces Unique $500 Million Venture to act as Seed Capital Funding for Earliest Stage Startups

Reporter: Stephen J. Williams, Ph.D.

Greylock Partners CEO Reid Hoffman announces a $500 million fund to help the earliest stage startups find capital.

See video below:

https://www.bloomberg.com/multimedia/api/embed/iframe?id=798828e9-7850-4c83-9348-a35d5fad3e1c

https://www.bloomberg.com/news/videos/2021-09-24/intv-sara-guoh-greylock-partners-video

See transcript from Bloomberg.com

00:00This is a lot of money for seed stage deals which is typicallysmaller. Why do you want to make seed such a priority.

00:09So see it has always been a priority for us. We’ve been activeat this stage for a long time and some of our biggest wins

00:15historically have been incubation and seed. So I think companieslike Workday and Palo Alto Networks and more recently abnormal

00:21and Snorkel. And then this year 70 percent of our investmentsyou must mints or seeds before we announce this fund. And so

00:29when we saw this level of opportunity we also want to make surewe had enough funding to really back entrepreneurs and to

00:36support them through their journey and make sure entrepreneursalso know they have different options at the seed for the type

00:41of partners they work with. Now at the seed stage you’re talkingabout companies in their infancy. How early are you investing. I

00:49mean is this ideas on a napkin stage with a couple ofentrepreneurs that you believe in or is it beyond that.

00:58So there definitely is a whole range. We don’t catch everysingle person. Like the day they left their job. Right. But you

01:04know abnormal was to see it in 2018 when it was a slide deck andtwo co-founders. We backed another company recently and self on

01:12first capital. That was a repeat founder we have history with.Similarly no product yet. Just an idea and an early team. And so

01:20the range of when we do see it really depends on when weencounter companies. We do like to get to know people as early

01:26as possible. And sometimes that’s the right time for us to writethe check. Obviously Greylock is a multi-stage venture venture

01:32capital firm and I think founders might have the question here.You know if you give me the seed funding we’ll follow on and

01:38reserves come out of that same bucket. And what could this meanin terms of a longer term relationship with Greylock. What’s the

01:46answer to that. So the first thing I’d start with is seeds forus our core investments. Right. So many firms look at them as

01:54options to then follow on. We look at seeds as investments we’retrying to make money on. We’re building a relationship for the

02:01long term to begin with. Right. So. So I’d start with that thenI’d say it is a third of our fund. So it is a big piece of our

02:09investing. And and you know there are many instances where wethen follow on and invest even more because our conviction

02:16continues or even grows. But the point of us doing seed is notjust a follow on it’s to make that investment. How big is each

02:24deal. I mean would you say that seed is the new series A.I think I think that.

02:33Well let’s see the market data would tell us that round sizesoverall have increased for the same level of progress. And I

02:41think that makes sense right. And the reason being the markethas become a lot smarter at the attractiveness of early stage

02:48technology opportunities. And so great returns in tech venturecapital over many years mean there’s more capital than ever and

02:57people are savvier about software and Internet companies. ButI’d say there is you know I think kind of the noble creature

03:04doesn’t matter so much. We think of it as being the firstinstitutional partner to go to a set of founders. The world is

03:12changing quickly. I mean we’re still in the middle of apandemic. And who would’ve known that you know working from home

03:16was going to be a thing 18 months ago. What are the trends thatyou are most excited about right now that you’re doubling down

03:22on at the seed stage.Yeah. So we invest across the technology spectrum business

03:30consumer. The one you just mentioned in terms of just the seachange of the pandemic in terms of how we do our work together

03:36as one. I’m really excited about but we’ve been we’ve beeninvesting in let’s say just this. There’s a shortage globally

03:44because the pandemic. But even before of human connection andand intimacy and people look for it online. And so we invest in

03:53companies like Dischord and Common ROOM and Promotion that helppeople connect more online. So that’s when we’ll continue to

04:00invest in. And then of course we’re investing across all of yourusual range of SAS social data A.I. etc. and then spending more

04:10and more time in fintech and crypto in particular. Now what arethe potential problems with seed stage. Is that at a certain

04:16point as the company develops maybe they pivot they change. Overtime they could potentially ultimately compete with another one

04:23of your core portfolio companies. How do you manage that.So it’s a good question but it is also something that doesn’t

04:30only happen at the scene and funnily enough Greylock has been aninvestor in several companies that were like great companies

04:37post pivot right. So like first semester and discord and nextdoor after they decided to be what they are today. And so that

04:46you know I’d start with the premise of our our philosophy isthat the company should do what’s best for the company. And we

04:53know our our philosophy is to be fully behind companies and notto go invest in a bunch of competitors in a sector just because

04:59we like this sector. But if that were to happen you know wewould we would just divide those interests within the firm and

05:06like make sure that there’s no information flow and just addressit in a reasonable way. I’ve talked with many of your partners

05:12over the years about investing in more women. And I’m curioushow you look at it as an opportunity to potentially you know

05:22spread the wealth a little bit across more women entrepreneurspeople of color people who historically haven’t gotten a chance

05:29in Silicon Valley and Silicon Valley hasn’t benefited from theirideas.

05:34OK. So I’d say this is an issue that’s near and dear to myheart. We are working on it. Two of the last three founders I

05:40backed are women. One is the seed stage founder. One of thefounders. I backed at the seed stage is Hispanic. But. But I

05:49would say you know one thing I want to make sure is clear. Likeyou want to back great founders from diverse backgrounds across

05:56the spectrum. And like we wouldn’t like do it more in seedbecause seed isn’t important. Because it is important to us.

06:02Right. It’s just across the portfolio. This is a priority.

From TechStartups

Source: https://techstartups.com/2021/09/22/greylock-partners-raises-500-million-invest-seed-stage-startups/

Greylock Partners raises $500 million to invest in seed-stage startups

Nickie LouisePOSTED ON SEPTEMBER 22, 2021


Greylock Partners has raised $500 million to invest exclusively in seed-stage startups. The announcement comes a year after the firm raised $1 billion for its 16th flagship fund to invest in early- and growth-stage tech startups.

Guo and general partner Saam Motamedi said in an interview the fund is part of an expansion of a $1.1 billion fund, which we reported last year, to $1.6 billion, The Information reported. The funding is among the industry’s largest devoted to seed investments, which often represent a startup’s first outside capital.

The pool of funds will give the 56-year-old venture capital firm the ability to write large checks at “lean-in valuations” and emphasize its commitment to early-stage investing, said general partner Sarah Guo. In a thread post on Twitter, Greylock said, “We at @GreylockVC  are excited to announce we’ve raised $500M dedicated to seed investing. This is the industry’s largest pool of venture capital dedicated to backing founders at day one.”

Press Release from Grelock

More articles on Venture Capital on this Online Open Access Journal Include:

youngStartup Ventures “Where Innovation Meets Capital” – First Round of VC Firms Announced, August 4th – 6th, 2020.

Real Time Coverage @BIOConvention #BIO2019: Dealmakers’ Intentions: 2019 Market Outlook June 5 Philadelphia PA

Podcast Episodes by THE EUROPEAN VC

Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 8, 2019: Deals and Announcements

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Read Full Post »

Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes

Reporter: Amandeep Kaur, B.Sc., M.Sc.

A recent study reports the development of an advanced AI algorithm which predicts up to five years in advance the starting of type 2 diabetes by utilizing regularly collected medical data. Researchers described their AI model as notable and distinctive based on the specific design which perform assessments at the population level.

The first author Mathieu Ravaut, M.Sc. of the University of Toronto and other team members stated that “The main purpose of our model was to inform population health planning and management for the prevention of diabetes that incorporates health equity. It was not our goal for this model to be applied in the context of individual patient care.”

Research group collected data from 2006 to 2016 of approximately 2.1 million patients treated at the same healthcare system in Ontario, Canada. Even though the patients were belonged to the same area, the authors highlighted that Ontario encompasses a diverse and large population.

The newly developed algorithm was instructed with data of approximately 1.6 million patients, validated with data of about 243,000 patients and evaluated with more than 236,000 patient’s data. The data used to improve the algorithm included the medical history of each patient from previous two years- prescriptions, medications, lab tests and demographic information.

When predicting the onset of type 2 diabetes within five years, the algorithm model reached a test area under the ROC curve of 80.26.

The authors reported that “Our model showed consistent calibration across sex, immigration status, racial/ethnic and material deprivation, and a low to moderate number of events in the health care history of the patient. The cohort was representative of the whole population of Ontario, which is itself among the most diverse in the world. The model was well calibrated, and its discrimination, although with a slightly different end goal, was competitive with results reported in the literature for other machine learning–based studies that used more granular clinical data from electronic medical records without any modifications to the original test set distribution.”

This model could potentially improve the healthcare system of countries equipped with thorough administrative databases and aim towards specific cohorts that may encounter the faulty outcomes.

Research group stated that “Because our machine learning model included social determinants of health that are known to contribute to diabetes risk, our population-wide approach to risk assessment may represent a tool for addressing health disparities.”

Sources:

https://www.cardiovascularbusiness.com/topics/prevention-risk-reduction/new-ai-model-healthcare-data-predict-type-2-diabetes?utm_source=newsletter

Reference:

Ravaut M, Harish V, Sadeghi H, et al. Development and Validation of a Machine Learning Model Using Administrative Health Data to Predict Onset of Type 2 Diabetes. JAMA Netw Open. 2021;4(5):e2111315. doi:10.1001/jamanetworkopen.2021.11315 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780137

Other related articles were published in this Open Access Online Scientific Journal, including the following:

AI in Drug Discovery: Data Science and Core Biology @Merck &Co, Inc., @GNS Healthcare, @QuartzBio, @Benevolent AI and Nuritas

Reporters: Aviva Lev-Ari, PhD, RN and Irina Robu, PhD

https://pharmaceuticalintelligence.com/2020/08/27/ai-in-drug-discovery-data-science-and-core-biology-merck-co-inc-gns-healthcare-quartzbio-benevolent-ai-and-nuritas/

Can Blockchain Technology and Artificial Intelligence Cure What Ails Biomedical Research and Healthcare

Curator: Stephen J. Williams, Ph.D.

https://pharmaceuticalintelligence.com/2018/12/10/can-blockchain-technology-and-artificial-intelligence-cure-what-ails-biomedical-research-and-healthcare/

HealthCare focused AI Startups from the 100 Companies Leading the Way in A.I. Globally

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/01/18/healthcare-focused-ai-startups-from-the-100-companies-leading-the-way-in-a-i-globally/

AI in Psychiatric Treatment – Using Machine Learning to Increase Treatment Efficacy in Mental Health

Reporter: Aviva Lev- Ari, PhD, RN

https://pharmaceuticalintelligence.com/2019/06/04/ai-in-psychiatric-treatment-using-machine-learning-to-increase-treatment-efficacy-in-mental-health/

Vyasa Analytics Demos Deep Learning Software for Life Sciences at Bio-IT World 2018 – Vyasa’s booth (#632)

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/05/10/vyasa-analytics-demos-deep-learning-software-for-life-sciences-at-bio-it-world-2018-vyasas-booth-632/

New Diabetes Treatment Using Smart Artificial Beta Cells

Reporter: Irina Robu, PhD

https://pharmaceuticalintelligence.com/2017/11/08/new-diabetes-treatment-using-smart-artificial-beta-cells/

Read Full Post »

The top 10 medtech M&A deals of 2020

Reporter: Aviva Lev-Ari, PhD, RN

SOURCE

Read Full Post »

National Resilience, Inc. is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption – the Acquisition of Two Premier Biologics Manufacturing Facilities: Boston and in Ontario, Canada

 

Reporter: Aviva Lev-Ari, PhD, RN

Resilience’s new facility, located at 500 Soldiers Field Rd., Boston, MA. (Photo: Business Wire) – The Genzyme-Sanofi Building

 

SAN DIEGO & BOSTON–(BUSINESS WIRE)–Resilience (National Resilience, Inc.), a new company building the world’s most advanced biopharmaceutical manufacturing ecosystem, announced it has acquired two premier commercial manufacturing facilities in North America, joining other facilities already in Resilience’s network to boost total capacity under management to more than 750,000 square feet.

“These locations will serve as hubs for the future of biopharma manufacturing, leading the way and shaping the future of Resilience.”

  • The acquired facilities include a 310,000-square-foot plant in Boston, MA, purchased from Sanofi; and in a separate transaction,
  • a 136,000-square-foot plant in Mississauga, Ontario, Canada.

Both facilities, which currently produce commercial, marketed products, will see significant investments as Resilience adds capacity and capabilities to produce new therapies at these locations. In addition, the company has offered employment to the existing plant staff and intends to add more jobs at each facility.

“We have big plans for these facilities including investing in new capacity, applying new manufacturing technologies, creating jobs and bringing in new customers,” said Rahul Singhvi, Sc.D, Chief Executive Officer of Resilience. “These locations will serve as hubs for the future of biopharma manufacturing, leading the way and shaping the future of Resilience.”

As part of its agreement with Sanofi, Resilience will continue to manufacture a marketed product at the Boston location. The facility plan includes a build out to facilitate multi-modality manufacturing and state-of-the-art quality laboratories to ensure safe, reliable supply to patients. The facility itself is certified ISO 14001 (Environmental management system), OSHAS 18001 (Health & safety management system) and ISO 50001 (Energy management system).​

This is currently the largest of several facilities in Resilience’s growing biologics and advanced therapeutics manufacturing network, with plans to acquire and develop other sites in the U.S. this year. The facility offers 24/7/365 production, multiple 2000L bioreactors capacity and multiple downstream processing trains, with investment in additional capabilities to come.

Our state-of-the-art flexible facility in Mississauga, Ontario, provides upstream, downstream and aseptic fill finish, and is designed to comply with cGMP. The plant has been inspected and approved by multiple regulatory bodies, and handles development and commercialized products.

About Resilience

Resilience (National Resilience, Inc.) is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. Resilience offers the highest quality and regulatory capabilities, and flexible and adaptive facilities to serve partners of all sizes. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience frees partners to focus on the discoveries that improve patients’ lives.

For more information, visit www.Resilience.com.

Contacts

Ryan Flinn
Head of Communications
Ryan.flinn@Resilience.com
510-207-7616

Read Full Post »

Podcast Episodes by THE EUROPEAN VC

Reporter: Aviva Lev-Ari, PhD, RN

 

Audio files are st:

The European VC

 

EPISODE #5: WILLIAM MCQUILLAN, FOUNDING PARTNER OF A VENTURE FIRM FOR GLOBALLY AMBITIOUS B2B COMPANIES

William is a founding partner of Frontline Ventures. Prior to starting Frontline, he was a founding employee at Ondra, an award-winning investment boutique that went from a 4 person team to 70+ employees in only 18 months. When Frontline was founded, William was 27 years old, making him the youngest VC ever to have raised a fund at that time (2012). Shortly after recording this episode William announced Frontline Fund III.

 

In this episode you will learn:

– How William has built a truly differentiated investment thesis for Frontline’s two funds.

– What William looks for in seed stage startups and why he believes integrity is all important and money cannot be the founder’s main driver.

– How William perceives the effects of Brexit and its implications for their investment strategy and work with startups.

– Why William is a supporter of founders taking a small bit of secondaries.

EPISODE #4: SHOMIT GHOSE, GP OF A SILICON VALLEY FIRM WITH 7 FUNDS UNDER ITS BELT

This episode runs contrary to what the European VC stands for and features an American VC from the Valley. However, the focus is on looking from the outside in, as well as carving out lessons learned from decades of collaboration across the Atlantic. Shomit Ghose is a General Partner of ONSET Ventures, a leading early stage venture firm operating out of Sand Hill Road, in Silicon Valley. With more than 130 startups and 7 funds under its belt, ONSET Ventures is a highly respected firm in the Valley. Shomit is a seasoned VC with multiple IPOs under his belt – both as an investor and as an entrepreneur.

 

In this episode you will learn:

– How the European and American VC landscapes differ and what we can learn from both.

– How to increase your presence and establish collaborations between US and European VCs.

– How to approach building a country-agnostic fund and the role of VCs, LPs and Institutions.

EPISODE #3 MICHAEL HANSEN, CEO OF A LEADING BUSINESS ANGEL ASSOCIATION IN EUROPE

Michael Hansen is the CEO of DanBAN, Denmark’s leading Business Angel Association. DanBAN consist of more than 200 active Angels who collectively invest in more than 30 M€ on an annual basis. Prior to joining DanBAN, Michael was the chief architect behind the sprawling investment environment around the Danish Robotics Cluster which is broadly recognized as one of the very strongest clusters for Robotics companies in Europe, if not the world.

In this episode, you will learn from a true investment cluster builder

– The importance of politicians making brave strategic decisions in promoting cluster development.

– The story of the Danish Robotics Cluster in which the first collaborative robots were hatched, counting with two acquisitions at a valuation of almost 1 billion EUR.

– How to work with national clusters to generate deal flow and fast track deals.

– Collaboration models between Business Angels and VCs.

EPISODE #2 STEPHAN MORAIS, FOUNDER AND MANAGING PARTNER OF A LEADING EARLY-STAGE DEEP TECH VC FIRM

Stephan Morais is the founder and Managing Partner of Indico Capital Partners, a leading early-stage deep tech VC firm. With a diversified background as an investment banker, consultant, entrepreneur and CEO, he has lived in 8 countries and 4 continents over the last 24 years, and acted as and advisor to politicians and European institutions. Prior to founding Indico, Stephan was an Executive Board Member at Caixa Capital, where he led investment rounds of many Portuguese global tech success stories.

In this episode, you’ll learn

– How Stephan tackled raising a VC fund and what to should look for in LPs

– How European VCs can push for policy developments that allow for more capital to be deployed into the industry

– What Europe can learn from other countries and regions

– What learnings Stephan has drawn from running an iberian fund

EPISODE #1 MARC LOHRMANN, MANAGING PARTNER OF A 120 M€ LIFE SCIENCE FUND

Marc Lohrmann is the Managing Partner of Vesalius Biocapital III, a 120 €M venture capital fund investing in late-stage companies in drug development, medical devices, diagnostics and eHealth, across Europe. Prior to joining Vesalius, Marc started eight life sciences companies, worked as an investment manager at a leading corporate VC and worked with several corporate finance boutiques focused on life sciences M&A transactions.

In this episode, you’ll learn

– How VBC III works as a country-agnostic VC fund and the main barriers to more funds investing across Europe.

– How investors without a natural sciences background can create value for Life Sciences companies and why founders find these investors a refreshing element in the board room.

– What Marc would love to change about European VC, what’s important when investing across Europe and what’s next for Marc.

 

 

 

 

SOURCE

https://www.theeuropeanvc.com/?utm_source=Sutardja%20Center%20Contacts&utm_campaign=f20d2f4f55-EMAIL_CAMPAIGN_2019_08_21_04_25_COPY_01&utm_medium=email&utm_term=0_8ae9d85a8f-f20d2f4f55-164676973

Read Full Post »

World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Reporter: Aviva Lev-Ari, PhD, RN

 

Davos Agenda

https://www.weforum.org/events/the-davos-agenda-2021

 

Adrian Monck, Managing Director, Public Engagement, public.affairs@weforum.org

日本語 | 中文 | عربي

World Leaders to Meet During Davos Agenda in a Crucial Year to Rebuild Trust

  • The Davos Agenda 2021 will convene under the theme: A Crucial Year to Rebuild Trust
  • The World Economic Forum will gather the world’s foremost leaders to address the economic, environmental, social and technological challenges following the COVID-19 pandemic 
  • More than 1,500 business, government and civil society leaders from over 70 countries will set the agenda for a critical year ahead and discuss how to catalyse impact in the rapidly advancing Fourth Industrial Revolution
  • The conclusions from the Davos Agenda week will feed into task forces working on global issues for the upcoming Special Annual Meeting in Singapore
  • For more information, please visit http://www.weforum.org; share on social media using the hashtag #DavosAgenda

Geneva, Switzerland, 18 January 2021 – The World Economic Forum Davos Agenda, taking place virtually on 25-29 January, will bring together the foremost leaders of the world to address the new global situation. Heads of state and government, chief executives and leaders from civil society will convene under the theme: A Crucial Year to Rebuild Trust.

The meeting will focus on creating impact, rebuilding trust and shaping the policies and partnerships needed in 2021.

“In the context of the COVID-19 pandemic, the need to reset priorities and the urgency to reform systems have been growing stronger around the world,” said Klaus Schwab, Founder and Executive Chairman of the World Economic Forum. “Rebuilding trust and increasing global cooperation are crucial to fostering innovative and bold solutions to stem the pandemic and drive a robust recovery. This unique meeting will be an opportunity for leaders to outline their vision and address the most important issues of our time, such as the need to accelerate job creation and to protect the environment.”

The COVID-19 pandemic has demonstrated that no institution or individual alone can address the economic, environmental, social and technological challenges of our complex, interdependent world. The pandemic has accelerated systemic changes that were apparent before its inception. The fault lines that emerged in 2020 now appear as critical crossroads in 2021. The Davos Agenda will help leaders choose innovative and bold solutions to stem the pandemic and drive a robust recovery over the next year.

The five programme themes are:

  1. Designing cohesive, sustainable, resilient economic systems (25 January)
  2. Driving responsible industry transformation and growth (26 January)
  3. Enhancing stewardship of the global commons (27 January)
  4. Harnessing the technologies of the Fourth Industrial Revolution (28 January)
  5. Advancing global and regional cooperation (29 January)

Special addresses from G20 heads of state and government and international organizations will provide crucial insights into a range of important issues in the year ahead. Participants will hear first-hand how these public figures will demonstrate leadership and drive action in areas such as the environment, jobs, and advances in innovation brought by the Fourth Industrial Revolution.

Heads of state and government include:

Xi Jinping, President of the People’s Republic of China; Narendra Modi, Prime Minister of India; Yoshihide Suga, Prime Minister of Japan; Emmanuel Macron, President of France; Angela Merkel, Federal Chancellor of Germany; Ursula von der Leyen, President of the European Commission; Giuseppe Conte, Prime Minister of Italy; Moon Jae-in, President of the Republic of Korea; Alberto Fernández, President of Argentina; Cyril Ramaphosa, President of South Africa; Pedro Sánchez, Prime Minister of Spain; Guy Parmelin, President of the Swiss Confederation and Federal Councillor for Economic Affairs, Education and Research; Ivan Duque, President of Colombia; Carlos Alvarado Quesada, President of Costa Rica; Nana Addo Dankwa Akufo-Addo, President of the Republic of Ghana; Kyriakos Mitsotakis, Prime Minister of Greece; Benjamin Netanyahu, Prime Minister of Israel; Abdullah II ibn Al Hussein, King of the Hashemite Kingdom of Jordan; Paul Kagame, President of Rwanda; Lee Hsien Loong, Prime Minister of Singapore, the host of the World Economic Forum Special Annual Meeting 2021.

Other world leaders are expected to confirm.

Leaders from international organizations, government agencies and central banks include:

António Guterres, Secretary-General, United Nations (UN); Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO); Kristalina Georgieva, Managing Director, International Monetary Fund (IMF); Amina Mohammed, Deputy Secretary-General, United Nations (UN); Achim Steiner, Administrator, United Nations Development Programme (UNDP); Phumzile Mlambo-Ngcuka, Undersecretary-General and Executive Director, United Nations Entity for Gender Equality and the Empowerment of Women (UN WOMEN); Dongyu Qu, Director-General, Food and Agriculture Organization of the United Nations (FAO); Inger Andersen, Executive Director, United Nations Environment Programme (UNEP); Henrietta Fore, Executive Director, United Nations Children’s Fund (UNICEF); David Beasley, Executive Director, United Nations World Food Programme (WFP); Fang Liu, Secretary-General, International Civil Aviation Organization (ICAO); Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA; Angel Gurría, Secretary-General, Organisation for Economic Co-operation and Development (OECD); Mauricio Claver-Carone, President, Inter-American Development Bank (IDB); Guy Ryder, Director-General, International Labour Organization (ILO); Jürgen Stock, Secretary-General, International Criminal Police Organization (INTERPOL); Fatih Birol, Executive Director, International Energy Agency (IEA); Rebecca Fatima Sta Maria, Executive Director, APEC Secretariat (Asia-Pacific Economic Cooperation).

Christine Lagarde, President, European Central Bank; François Villeroy de Galhau, Governor of the Central Bank of France; Andrew Bailey, Governor of the Bank of England.

The private sector will be represented by more than 1,000 leaders from the Forum’s member and partner organizations. Seven of the top ten companies by market capitalization are engaged year-round with the Forum and many will participate in The Davos Agenda week. As a working meeting to advance ongoing project work, more than 500 chief executives and chairpersons will take part in sessions throughout the week.

Leaders from civil society are a critical voice in shaping the agenda. Those taking part in the meeting include:

Seth Berkley, Chief Executive Officer, Gavi, the Vaccine Alliance; Gabriela Bucher, Executive Director, Oxfam International; Sharan Burrow, General Secretary, International Trade Union Confederation (ITUC); Hindou Oumarou Ibrahim, President, Association for Indigenous Women and Peoples of Chad (AFPAT); Marco Lambertini, Director-General, WWF International; Laura Liswood, Secretary-General, Council of Women World Leaders; Delia Ferreira Rubio, Chair, Transparency International; Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria (GF). 

Drawn from over 10,000 civic-minded young leaders, members of the World Economic Forum’s Global Shapers, Young Global Leaders, Technology Pioneers and Social Entrepreneurs communities will bring unique perspectives to The Davos Agenda.

Flagship reports, initiatives, and the latest book on Stakeholder Capitalism 

On January 25, Professor Schwab will release his latest book, titled “Stakeholder Capitalism: A Global Economy that Works for Progress, People and Planet.” It explores how societies can build the future post-COVID, and builds on the Forum’s 50-year-old advocacy of the stakeholder approach.

The World Economic Forum will release its Global Risks Report 2021 on 19 January. The flagship report is an important marker for prioritizing action in public and private sectors in the year ahead.

The Davos Agenda will also mark the launch of several World Economic Forum initiatives to accelerate the race to net-zero emissions, to champion new standards for racial justice, to ensure artificial intelligence is developed ethically and in the global public interest and to close the digital divide. More details on these initiatives and others will be disclosed at the meeting.

Opening Event and Crystal Awards

The meeting will be preceded by the Opening Event, available on YouTube on Sunday 24 January at 19.00 CET, featuring a welcome from Klaus Schwab and a special address by Guy Parmelin, President of the Swiss Confederation, just before the 27th Crystal Awards hosted by Hilde Schwab, Chairperson and Co-founder, Schwab Foundation for Social Entrepreneurship, and the photographer Platon.

The awards will be followed by the world premiere of “See Me: A Global Concert.” The official programme of The Davos Agenda will begin on 25 January.

Notes to editors

Media registration and sign-up

Explore the guide on how to follow and embed sessions on your website here

Watch the livestreamed sessions here

Follow the Forum on Twitter via @wef@davos and join the conversation using #DavosAgenda | Instagram | LinkedIn | TikTok | Weibo | Podcasts

Become a fan of the Forum on Facebook

Read the Forum Agenda also in French | Spanish | Mandarin | Japanese

Check out the Forum’s Strategic Intelligence Platform and Transformation Maps

Watch Forum videos

Learn about the Forum’s impact

Subscribe to Forum news releases and Podcasts

SOURCE

From: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

Reply-To: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

Date: Monday, January 18, 2021 at 9:37 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Read Full Post »

Venture Summit Virtual Connect West, March 16th -18th 2021 featuring a dedicated Lifesciences / Healthcare Track

Reporter: Aviva Lev-Ari, PhD, RN

 

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

 

UPDATED on 2/17/2021

Venture Summit Virtual Connect West Early Bird rates were extended to this Thursday, February 18th at midnight (EST). Would it be possible to share the dedicated discount code LPBIVIP again with your network? Included updated social media copy below.

The discount code will still operate when the rates increase but applicants should apply asap to lock in the lowest possible rates. Registration closes around March 11th.

Partial roster of over 170 VCs and Angels Confirmed to Speak and Judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Coleman Adams, Partner, CEVG | Dan Altschuler Malek, Managing Partner, Unovis Asset Management | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | Salman Azhar, Founding Partner & Managing Director, Azhar Private Equity | Afonso Babo, Co-managing director, COREangels Impact | Sion Balass, Partner, The Group Ventures | Assaf Barnea, CEO, Sanara Ventures | Hasan Basrai, Associate, Information Venture Partners | Randy Berholtz, Investor Judge, Mesa Verde Venture Partners | Ned Berman, Senior Associate, Differential Ventures | Reetika Bhardwaj, Associate, ARCH Venture Partners | Udit Bhatnagar, Vice President, McRock Capital | Jason Blumberg, CEO/Managing Partner, Energy Foundry | Christopher Booker, Partner, Frist Cressey Ventures | Alice Brooks, Principal, Khosla Ventures | Alex Brufsky, Venture Partner, 1435 Capital | Edouard Bulteau, Principal, Total Carbon Neutrality Ventures | Ryuk Byun, Associate, Aisling Capital | James Carroll, Managing Partner, CC Angel Investments | Adam Carson, Operating Partner, Point72 Ventures | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Andre Chabaneix, Associate, Blue Bear Capital | Iris Chan, Partner, Mighty Capital | Ray Chan, Managing Director, K5 Ventures | Jonathan Charles, Director, Samsung Catalyst Fund | Elizabeth Cho-Fertikh, Co-Founder & Managing Director, MEDA Angels | Ryan Chou, Investment Associate, JetBlue Technology Ventures | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Darren Cooke, Investor and Board Member, Life Science Angels | Amy Coveny, Managing Partner, Quake Capital | Rick Cutright, Technology Principal, OGCI Climate Investments | Joe Darcy, Principal, IDEA Fund Partners | Rahul Daryanani, Investor, Touchdown Ventures | Timur Davis, Principal, Munich Re Ventures | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Investment Partner, Joyance Partners | Eric Desai, Partner, Greenhouse Capital Partners | Philip Deutch, Partner, NGP ETP | Dixon Doll, Co-Founder & Partner Emeritus, DCM Ventures | Francesco Draetta, Principal, Omega Funds | Vikki Dunn, Operating Partner, Energy Innovation Capital | Amy Dyck, Associate, Framework Venture Partners | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Ali Farahanchi, Managing Director, DHVC | Andrew Felbinger, Investor, Urban Innovation Fund | Manny Fernandez, Angel Investor, SF Angels Group | Mark Fields, Partner, Alsop Louie Partners | Carolin Funk, Investment Director, Blue Bear Capital | Tarik Galijasevic, Managing Director, Allstate Strategic Ventures | Elena Gantvarg, Principal, Flint Capital | Chris Garabedian, CEO, Xontogeny | Daisy Garcia, Investment Analyst, JetBlue Technology Ventures | Joe Garcia, Venture Fellow, Rethink Impact | Selma Gasc, Investment Analyst, 360 Capital | Gary Gershony, Founding General Partner, BayMed Venture Partners | Michal Geva, Co-Founder and Managing Partner, Triventures | Shmuel Gniwisch, Managing Partner/Co-founder, Kli Capital | David Goldberg, General Partner, Alpaca VC | Garrett Goldberg, Partner, Bee Partners | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Emi Gonzalez, Senior Principal, Social Starts | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Deepak Gupta, Managing Partner, Blue Bear Ventures | Katie Hayes, Director, Wittington Ventures | Yashwanth Hemaraj, Partner, Benhamou Global Ventures | Thomas Henry, Co-Founder COO, Eunike Ventures | Robert Hess, Angel Investor, Life Science Angels | David Hornik, Partner, August Capital | Kirsten Horning, Principal, XRC Labs | Galit Horovitz, Co-founder, Welltech1 | Conor Hunt, Principal, 1435 Capital | Noel Jee, Principal, Illumina Ventures | Ben Jen, Managing Director, Ben Jen Holdings | Denis Kalyshkin, Principal, I2BF Global Ventures | Tomas Kemtys, Partner, Contrarian Ventures | Hunter Kettering, VC, Red Cedar Ventures | Maureen Klewicki, Investor, Crosscut Ventures | Howard Ko, Principal, Morpheus Ventures | John-Paul Lake, Managing Partner, Kern Venture Group | Rachel Lauren, Analyst, Bertelsmann Digital Media Investments | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Alicia Lenis, Vice President, Chrysalix Venture Capital | Todd Lewis, VP, Prologis Ventures, Prologis Ventures | Ephraim Lindenbaum, Managing Director, Advance Ventures | Charles Ling, Investment Director, Tsingyuan Ventures | Brian Litvak, Market Development, Aster Capital | Jim Lockheed, Principal, JetBlue Technology Ventures | Patrick Lord, Partner – Fintech, Truffle Capital | Eric Lui, Venture Partner, HCG Global Partners | Vincent Lui, Sr. Director Corporate Ventures, SK Telecom Ventures | Shailendra Mahajan, Managing Director, Maxim Ventures | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Radhika Malik, Investment Manager, Samsung Catalyst Fund | Alex Mayall, Associate, Anthemis Group | Melissa McCracken, Principal, Nextech Invest | Maulik Mehta, Investor, Arc Ventures | David Mendez, Managing Partner, Good Growth Capital | Laurie Menoud, Partner, At One Ventures | Inka Mero, Founder & Managing Partner, Voima Ventures | Pedro Mesquita, Investment Analyst, Mindset Ventures | Khash Mohajerani, Director, BWE LLP | Matt Murphy, Partner, Montage Ventures | Olivia Musmanno, Senior Associate, Quake Capital | Molly O’Shea, Investor, NYL Ventures | Gilbert Ohana, Managing Partner, FinTLV Ventures | Victor Orlovski, Managing Partner, Fort Ross Ventures | Shamik Parekh, Investment Associate, Octopus Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Michael Peri, Senior Vice President, NFP Ventures | Michael Perry, Associate, Link Ventures | Daniel Pianko, Managing Director, Achieve Partners | Patricia Poon, Director, Belmond Capital | Robert Poor, Advisor, Good Growth Capital | Ulrich Quay, Managing Partner, BMW i Ventures | Suraj Rajwani, Managing Partner, DoubleRock LLC | Mark Ralph, Executive Director, Boehringer Ingelheim Venture Fund | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Marie-Christine Razaire, Associate, Northwestern Mutual Future Ventures | Julia Reichelstein, Investor, Piva Capital | John Robinson, Partner, Mazarine Ventures | Carolina Rojas, Ventures Analyst, NFP Ventures | Stephen Roland, Associate, Swiftarc Ventures | Alexander Ross, Investment Director, Illuminate Financial | Joseph Rothman, Venture Partner, AlphaPrime Ventures | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Abinav Sankar, Partner, Sopris Capital | Stephanie Sarelakos, VP, Investments, The Venture Collective | Massimo Schäppi, Partner, Tomahawk .VC | Reese Schroeder, Investor, Allstate Strategic Ventures | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Partner, Fort Ross Ventures | Shounok Sinha, Principal, Venture Investing, Constellation Technology Ventures | Michelle Snyder, Partner, McKesson Ventures | Vivek Soni, Venture Partner, S CAP CleanTech | Peter Sopher, Manager, Clean Energy Ventures | Kumar Sripadam, GP, Elevate Capital | Anish Srivastava, Founder & CEO, Vinaj Ventures | Alexander Starchenko, Managing Partner, First Imagine! Ventures | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Ning Sung, Investor, Sandhill Angels | Daniel Teo, Managing Partner, Hunniwell Lake Ventures | Byron Thom, Principal, Framework Venture Partners | Abhinav Tiwari, General Partner, Owl Capital | Erica Van, Investor, Charles River Ventures | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Joe Vasquez, Venture Partner, Revel Partners | Alexander Vavilov, Investment Manager, iTech Capital | Mark Vreeke, Founder, Chemical Angel Network | Jordan Wahbeh, Managing Partner, SV Venture Group | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Isaiah Washington, Analyst, Insight Partners | Lauren Weston, Associate, Thomvest Ventures | Sarah Wolter, Principal, FinTech Collective | Minjia Wu, Principal, SOSV | Yating Xia, Investor, TCL | Steve Yaskin, Venture Partner, Scale Up Ventures | Juan Zavala, Principal, New Markets Venture Partners | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Chen Zhou, Investor, Samsung Catalyst Fund and many more…

Regards,

 

Gil

 

Gil Garalnick

Senior Associate

youngStartup Ventures

 

“Where Innovation Meets Capital”

 

p: 212.202.1002 ext 208

e: gil@youngstartup.com

u: www.youngstartup.com

 

 

UPDATED on 1/21/2021

Leaders in Pharmaceutical Business Intelligence is pleased to announce its sponsorship and invite you to join us at Venture Summit Virtual Connect West, featuring a dedicated Lifesciences / Healthcare Track

Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)

 

* Call for Top Innovators Details below

 

 

Venture Summit Virtual Connect West

Where Innovation Meets Capital

 

March 16th -18th 2021

 

 

Friends,

 

Come meet, interact and network online with more than 1,500 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit Virtual Connect West being held virtually on March 16th-18th 2021, featuring a dedicated Lifesciences / Healthcare track.

 

Whether you’re a Lifesciences /Healthcare startup seeking capital and exposure, or an investor seeking new deals, the Lifesciences / Healthcare track at Venture Summit Virtual Connect West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, Venture Summit Virtual Connect West will bring together over 1,500 VCs, Corporate VCs, Angel Investors, ‎Industry executives and founders of venture backed, emerging and early stage companies; will feature ‎One-on-One networking (online), more than 150 VCs as speakers/ judges; Venture panels, startup workshops, presentations by more than 100 Top Innovators and ‎Keynotes.

 

Partial roster of over VCs and Angels confirmed to speak and judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Dan Altschuler Malek, Managing Partner, Unovis Asset Management | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | Sion Balass, Partner, The Group Ventures | Randy Berholtz, Senior Advisor, Mesa Verde Venture Partners | Ned Berman, Senior Associate, Differential Ventures | Udit Bhatnagar, Vice President, McRock Capital | Christopher Booker, Partner, Frist Cressey Ventures | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Darren Cooke, Investor and Board Member, Life Science Angels | Amy Coveny, Managing Partner, Quake Capital | Joe Darcy, Principal, IDEA Fund Partners | Rahul Daryanani, Investor, Touchdown Ventures | Timur Davis, Principal, Munich Re Ventures | Jun Deng, Investment Partner, Joyance Partners | Philip Deutch, Partner, NGP ETP | Dixon Doll, Co-Founder & Partner Emeritus, DCM Ventures | Vikki Dunn, Operating Partner, Energy Innovation Capital | Amy Dyck, Associate, Framework Venture Partners | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Ali Farahanchi, Managing Director, DHVC | Andrew Felbinger, Investor, Urban Innovation Fund | Mark Fields, Partner, Alsop Louie Partners | Carolin Funk, Investment Director, Blue Bear Capital | Elena Gantvarg, Principal, Flint Capital | Gary Gershony, Founding General Partner, BayMed Venture Partners | David Goldberg, General Partner, Alpaca VC | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Emi Gonzalez, Senior Principal, Social Starts | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Katie Hayes, Director, Wittington Ventures | Robert Hess, Angel Investor, Life Science Angels | Kirsten Horning, Principal, XRC Labs | Ben Jen, Managing Director, Ben Jen Holdings | Hunter Kettering, VC, Red Cedar Ventures | Howard Ko, Principal, Morpheus Ventures | Rachel Lauren, Analyst, Bertelsmann Digital Media Investments | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Alicia Lenis, Vice President, Chrysalix Venture Capital | Todd Lewis, VP, Prologis Ventures, Prologis Ventures | Charles Ling, Investment Director, Tsingyuan Ventures | Jim Lockheed, Principal, JetBlue Technology Ventures | Patrick Lord, Partner – Fintech, Truffle Capital | Eric Lui, Venture Partner, HCG Global Partners | Vincent Lui, Sr. Director Corporate Ventures, SK Telecom Americas | Shailendra Mahajan, Managing Director, Maxim Ventures | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Maulik Mehta, Investor, Arc Ventures | David Mendez, Managing Partner, Good Growth Capital | Laurie Menoud, Partner, At One Ventures | Pedro Mesquita, Investment Analyst, Mindset Ventures | Khash Mohajerani, Director, BWE LLP | Matt Murphy, Partner, Montage Ventures | Molly O’Shea, Investor, NYL Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Daniel Pianko, Managing Director, Achieve Partners | Robert Poor, Advisor, Good Growth Capital | Ulrich Quay, Managing Partner, BMW i Ventures | Suraj Rajwani, Managing Partner, DoubleRock LLC | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Marie-Christine Razaire, Associate, Northwestern Mutual Future Ventures | John Robinson, Partner, Mazarine Ventures | Stephen Roland, Associate, Swiftarc Ventures | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Massimo Schäppi, Partner, Tomahawk .VC | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Kumar Sripadam, GP, Elevate Capital | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Byron Thom, Principal, Framework Venture Partners | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Joe Vasquez, Venture Partner, Revel Partners | Mark Vreeke, Founder, Chemical Angel Network | Jordan Wahbeh, Managing Partner, SV Venture Group | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Lauren Weston, Associate, Thomvest Ventures | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…

 

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive a unique discount of an additional 20% off the existing “early bird” savings. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

 

Register Today & Save Click here http://bit.ly/3840e3D    . (Use promo code “LPBIVIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

 

We look forward to seeing you there.

 

Leaders in Pharmaceutical Business Intelligence & youngStartup Ventures

 

 

 

Leaders in Pharmaceutical Business Intelligence is pleased to announce its sponsorship and invite you to join us at Venture Summit Virtual Connect West, featuring a dedicated Lifesciences / Healthcare Track

Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)

 

* Call for Top Innovators Details below

  

Venture Summit Virtual Connect West

Where Innovation Meets Capital

 

March 16th -18th 2021

Register Today & Save

Click here http://bit.ly/3840e3D   

(Use promo code “LPBIVIP”)

Friends,

 

Come meet, interact and network online with more than 1,500 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit Virtual Connect West being held virtually on March 16th-18th 2021, featuring a dedicated Lifesciences / Healthcare track.

Whether you’re a Lifesciences /Healthcare startup seeking capital and exposure, or an investor seeking new deals, the Lifesciences / Healthcare track at Venture Summit Virtual Connect West presented by youngStartup Ventures – is the event of the year you won’t want to miss. 

A highly productive venture conference, Venture Summit Virtual Connect West will bring together over 1,500 VCs, Corporate VCs, Angel Investors, ‎Industry executives and founders of venture backed, emerging and early stage companies; will feature ‎One-on-One networking (online), more than 150 VCs as speakers/ judges; Venture panels, startup workshops, presentations by more than 100 Top Innovators and ‎Keynotes.

 

Partial roster of VCs and Angels confirmed to speak and judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Timur Davis, Principal, Munich Re Ventures | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Andrew Felbinger, Investor, Urban Innovation Fund | Gary Gershony, Founding General Partner, BayMed Venture Partners | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Kirsten Horning, Principal, XRC Labs | Hunter Kettering, VC, Red Cedar Ventures | Rachel Lauren, Analyst, BDMI | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Matt Murphy, Partner, Montage Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nia Stefani, CEO, Xnergy Financial | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive a unique discount of an additional 20% off the existing “early bird” savings. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

 

Register Today & Save Click here http://bit.ly/3840e3D   

(Use promo code “LPBIVIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

  

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here. 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

  

We look forward to seeing you there.

 

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

 

 

 

 

 

LinkedIn

Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16th– 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Whether you are a Lifesciences / Healthcare investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, Venture Summit | Virtual Connect is one event you won’t want to miss.

 

Twitter

Join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16th– 18th 2021. Dedicated Lifesciences/Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Where do #startups connect with over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators? #VSVC Venture Summit Virtual Connect West being held on March 16th – 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register at  http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Facebook

Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect West being held on March 16th – 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

 

 

Read Full Post »

Biomolecular Condensates: A new approach to biology originated @MIT – Drug Discovery at DewPoint Therapeutics, Cambridge, MA gets new leaders, Ameet Nathwani, MD (ex-Sanofi, ex-Novartis) as Chief Executive Officer and Arie Belldegrun, PhD (ex-Kite Therapeutics) on R&D

Curator & Reporter: Aviva Lev-Ari, PhD, RN

 

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

A new approach to biology

“The real voyage of discovery consists, not in seeking new landscapes, but in having new eyes.” Marcel Proust

Starting with the study of P granules in C.elegans embryos in 2009, Tony Hyman, working with his collaborators like Frank Julicher, Cliff Brangwynne, Simon Alberti, Mike Rosen, and Rohit Pappu, began to unravel the mysteries of biomolecular condensates. These scientists realized that P granules behave like liquid droplets that form by phase separation (think of oil droplets in salad dressing) and called them condensates.

In subsequent studies, they found to their surprise that many compartments inside cells had the behavior of condensates: they are liquid-like and form by phase separation.

Inspired by the work of Tony and his colleagues, Richard Young, Phillip Sharp, and Arup Chakraborty at MIT applied these approaches to the study of gene expression, similarly shedding light on many important questions in gene control.

a video thumbnail

 

Press releases and Dewpoint in the news

 
  • Dewpoint Therapeutics Appoints Ameet Nathwani as Chief Executive Officer

    Dewpoint

  • New York Times interviews Rick Young and Amy Gladfelter on the role of condensate “droplets” in COVID-19

    New York Times

  • Dewpoint Therapeutics raises $77 million to go after ‘undruggable’ diseases

    Boston Globe

  • Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

    Endpoint News

  • Dewpoint Therapeutics to put ‘pedal to the metal’ with $77M round

    FierceBiotech

  • Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates

    Dewpoint

  • 21 biotech startups that are set to take off, according to top VCs

    Business Insider

  • Proteins — and labs — coming together to prevent Rett Syndrome

    Whitehead Institute

  • Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

    Dewpoint

  • Discovery of how cancer drugs find their targets could lead to a new toolset for drug development

    Whitehead Institute

SOURCE

https://dewpointx.com/news/

Other related article published in this Online Open Access Scientific Journal include: 

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

https://pharmaceuticalintelligence.com/2017/10/04/economic-potential-of-a-drug-invention-prof-zelig-eshhar-weitzman-institute-registered-the-patent-versus-a-cancer-drug-in-clinical-trials-car-t-as-a-case-in-point-developed-by-kite-pharma-unde/

Read Full Post »

Older Posts »

%d bloggers like this: